WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Novo Nordisk A/S - Growth / Value Index


NVO - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Excellent Score of 95.00
   Undervalued - Price to Intrinsic Value of 0.0121
   Price to Earning Ratio is 2.24 and EV to EBITDA is 1.86 suggesting company is undervalued.
   Tremendous increasing in Book Value last 3 year
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 2.23 2.45 -18.12 %
Price to Book 1.81 1.72 -26.62 % 1.47
Price to Sales 0.792 0.850 -20.97 %
Enterprise Value to EBITDA Multiple 1.85 2.70 18.19 %


NVO - Profitability Highlights

Profitability Analysis

   Earning Yield of 44.59 %
   Tremendous increasing trend in Net Profit for last 3 year
   Excellent Net Margin for last 3 years
   Over the last 3 years, the company has achieved Incredible Return on Equity
   Over the last 3 years, the company has achieved Incredible Return on Assets
   Strong Return On Capital Employed of 42.16
   Company Earning excess return
   During the past twelve months, the company has given a strong Return On Equity of 81.29%
   During the past twelve months, the company has given a strong Return On Asset of 25.20%
   During the past twelve months, the company has given a strong Net Margin of 35.61%
   All key Trailing Twelve Months Margin growing by 15 %
   EBITDA is continuously increasing for last 3 Years
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 81.29 70.38 -10.38 % 15.77
Return On Asset 25.20 21.68 -18.52 % 5.50
Net Profit Margin 35.61 34.78 -3.48 % 34.48
Operating Profit Margin 45.78 44.19 10.49 % 43.52
EBITDA Margin 46.72 41.92 -13.79 % 47.22


Highlights
Market Cap187325 M
Enterprise Value269029 M
Price/Book TTM1.81
Outstanding Share3368.56 M
Float/ Outstanding Share94.64%
Dividend Yield2.94 %
Share Holding
Guru Numbers
Price/Graham No0.413
Peter Lynch Ratio9.96
Piotroski F Score6.00
Altman Z Score2.06
Sloan Ratio0.234
Peter Lynch Fair Value401.53


NVO - Growth Highlights

Growth Analysis

   Tremendous increasing trend in total sale last 3 year
   Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 311938 M 25.03 % 1.58 %
Gross Profit 261870 M 25.13 % 1.82 %
EBITDA 145737 M 7.79 % 4.61 %
Net Profit 111068 M 20.68 % 8.72 %
EPS 24.99 22.13 % NA


NVO - Stability Highlights

Stability Analysis
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.679 222.01 % 0.591
Cash Ratio 0.121 -32.13 %
Quick Ratio 0.552 -13.17 % 0.564
Shareholders Equity 30.80 -9.09 %
Debt to EBITDA 0.800 302.27 %


Historical Valuation Ratios of Novo Nordisk A/S

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Novo Nordisk A/S

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Novo Nordisk A/S

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Novo Nordisk A/S

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)